[Candida antigen and antibody kinetics during antifungal therapy in non-neutropenic intensive care patients].
The present study aimed at determining Candida antigen and antibody kinetics during antifungal therapy. 115 non-neutropenic patients with a stay of more than 5 days in an interdisciplinary intensive care unit during a period of 2 years were reviewed. Routinely measured Candida antigen and antibody titers were evaluated at the beginning and during antifungal therapy. In 67 patients serological data were evaluable in defined time slots. Under fluconazole therapy (FT) the median of Candida antigen (Ramco) was 1:4 and did not change significantly. Candida antibody level increased from 1:80 to 1:320. Initial titers between FT and amphotericin B/5-fluorocytosine therapy (AT) showed a significant difference. During AT antigen titers decreased from 1:8 to 1:4 while antibody titers kept constant at a level of 1:160.
Wauer
H J
HJ
Universitätsklinik für Anästhesiologie und Operative Intensivmedizin der Charité, Schumannstr. 20/21, D-10117 Berlin, Germany. helmar.wauer@charite.de
West
C
C
Tietz
H J
HJ
Kox
W J
WJ
D000666:Amphotericin B / Q000627:therapeutic use; D000908:Antibodies, Fungal / Q000097:blood*; D000935:Antifungal Agents / Q000627:therapeutic use*; D000946:Antigens, Fungal / Q000097:blood*; D002175:Candida / Q000276:immunology*; D002177:Candidiasis / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D015725:Fluconazole / Q000627:therapeutic use; D005437:Flucytosine / Q000627:therapeutic use; D006801:Humans; D007362:Intensive Care Units; D009504:Neutrophils
D000908:Antibodies, Fungal; D000935:Antifungal Agents; D000946:Antigens, Fungal; D000666:Amphotericin B; D015725:Fluconazole; D005437:Flucytosine